Su PL, Tsai JS, Yang SC, et al. - Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients with T790M mutations who were pretreated with first- or second-generation epidermal growth factor receptor tyrosine-kinase inhibitors and were taking osimertinib at two tertiary referral centres between August 2015 and July 2019. As revealed in Cox proportional hazards model adjusted for possible confounders, better overall survival (OS) was conferred by osimertinib-based combination therapy vs chemotherapy alone. Thus, the hypothesis that osimertinib-based combination therapy is related to improved OS in cases with clinical progression after the use of osimertinib, is supported by the findings of this study.